Leah Gibson - Cybin VP Communications

CYBN Stock  USD 9.91  0.13  1.33%   

Insider

Leah Gibson is VP Communications of Cybin Inc
Address 100 King Street West, Toronto, ON, Canada, M5X 1C9
Phone908 764 8385
Webhttps://www.cybin.com

Cybin Management Efficiency

The company has return on total asset (ROA) of (0.3271) % which means that it has lost $0.3271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4907) %, meaning that it created substantial loss on money invested by shareholders. Cybin's management efficiency ratios could be used to measure how well Cybin manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of December 2024, Return On Tangible Assets is likely to grow to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.2. At this time, Cybin's Total Assets are very stable compared to the past year. As of the 16th of December 2024, Non Current Assets Total is likely to grow to about 87.7 M, while Non Currrent Assets Other are likely to drop (292.2 K).
Cybin Inc currently holds 291 K in liabilities. Cybin Inc has a current ratio of 7.68, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cybin's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MD MAMind Medicine
44
Magnus HalleGH Research PLC
27
JD MBAImmix Biopharma
N/A
Michael PitznerMolecular Partners AG
N/A
Ryan BakerIteos Therapeutics
N/A
Patrick AmstutzMolecular Partners AG
49
Thomas SchwerzmannMolecular Partners AG
N/A
Gabriel BAImmix Biopharma
37
Ian LeitchOpthea
61
Andreas EMBAMolecular Partners AG
58
MAICD MAICDOpthea
48
Peter MBABio Path Holdings
75
Elizabeth EvansVaccinex
51
Michael CarruthersEdgewise Therapeutics
66
Alexander ZurcherMolecular Partners AG
49
Christian AngermayerATAI Life Sciences
46
Nandan BSImmix Biopharma
62
Badreddin EdrisEdgewise Therapeutics
37
Theis MDGH Research PLC
48
Karen CashmereZyVersa Therapeutics
72
CPA CPAOpthea
63
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. It has also developed EMBARK, a psychedelic-assisted psychotherapy. Cybin operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 50 people. Cybin Inc (CYBN) is traded on NYSE MKT Exchange in USA. It is located in 100 King Street West, Toronto, ON, Canada, M5X 1C9 and employs 50 people. Cybin is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Cybin Inc Leadership Team

Elected by the shareholders, the Cybin's board of directors comprises two types of representatives: Cybin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cybin. The board's role is to monitor Cybin's management team and ensure that shareholders' interests are well served. Cybin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cybin's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alex Nivorozhkin, Chief Officer
Greg Cavers, Chief Officer
Gabriel Fahel, Chief Secretary
John Kanakis, CoFounder
Douglas Drysdale, Chief Officer
Erica Olson, VP Controller
Eric LLB, President CoFounder
George Tziras, Chief Director
Aaron Bartlone, Chief Officer
Lori Challenger, Ethics Compliance
Sara Somerset, Chief Officers
Paul Glavine, Chief CoFounder
MD DFAPA, Senior Development
Leah Gibson, VP Communications
LLB LLB, Pres CoFounder

Cybin Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cybin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Cybin

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cybin position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cybin will appreciate offsetting losses from the drop in the long position's value.

Moving against Cybin Stock

  0.73MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.55PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
  0.5JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.48LLY Eli LillyPairCorr
  0.47VALN Valneva SE ADRPairCorr
The ability to find closely correlated positions to Cybin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cybin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cybin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cybin Inc to buy it.
The correlation of Cybin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cybin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cybin Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cybin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cybin Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cybin's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cybin Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cybin Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cybin Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cybin. If investors know Cybin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cybin listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.01)
Return On Assets
(0.33)
Return On Equity
(0.49)
The market value of Cybin Inc is measured differently than its book value, which is the value of Cybin that is recorded on the company's balance sheet. Investors also form their own opinion of Cybin's value that differs from its market value or its book value, called intrinsic value, which is Cybin's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cybin's market value can be influenced by many factors that don't directly affect Cybin's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cybin's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cybin is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cybin's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.